Table S5.

Direct meta-analysis of American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 outcomes: licensed DMARD monotherapy versus placebo in DMARD-experienced patients

Treatment	Fixed effect		Random effects
	OR v PLA (95% CI)	P-value	OR v PLA (95% CI)	P-value
ACR 20
ADA 40 mg/2 weeks	5.280 (3.211, 8.680)	<0.001	5.298 (3.226, 8.701)	<0.001
ETN 2 25 mg/week	11.34 (4.958, 25.938)	<0.001	11.34 (4.958, 25.938)	<0.001
TOC 8 mg/kg/4 weeks	28.069 (9.689, 81.318)	<0.001	28.069 (9.689, 81.318)	<0.001
ACR 50
ADA 40 mg/2 weeks	4.633 (2.398, 8.953)	<0.001	4.588 (2.374, 8.866)	<0.001
ETN 2 25 mg/week	12.532 (4.159, 37.76)	<0.001	12.532 (4.159, 37.76)	<0.001
TOC 8 mg/kg/4 weeks	34.667 (4.459, 269.54)	0.001	34.667 (4.459, 269.54)	0.001
ACR 70
ADA 40 mg/2 weeks	10.861 (3.045, 38.736)	<0.001	10.126 (2.837, 36.145)	<0.001
ETN 2 25 mg/week	25.714 (3.215, 205.639)	0.002	25.714 (3.215, 205.639)	0.002
TOC 8 mg/kg/4 weeks	40.714 (2.276, 728.176)	0.012	40.714 (2.276, 728.176)	0.012

Notes: SUL not connected to placebo, so no direct results; P < 0.05 is statistically significant.

Abbreviations: ADA, adalimumab; CI, confidence interval; DMARD, disease-modifying antirheumatic drug; ETN, etanercept; OR, odds ratio; PLA, placebo; SUL, sulfasalazine; TOC, tocilizumab.